14 results about "Human telomerase" patented technology

The invention provides a recombinant herpes simplex virus and a herpes simplex virus modification method. The herpes simplex virus modification method comprises the step of replacing an ICP4 protein coding gene in a herpes simplex virus genome containing an infected cell protein 4 (ICP4) gene with an hTERTp-fluorescent protein expression cassette. The expression cassette comprises an hTERTp promoter and a fluorescent protein coding sequence controlled by the hTERTp promoter, and the transcription direction is opposite to that of an ICP4 promoter in a genome. The hTERTp-fluorescent protein expression cassette in the recombinant virus obtained by the method disclosed by the invention can be normally expressed in response to telomerase activity. Therefore, the recombinant virus is capable of expressing a fluorescent protein, such as mBaoJin, in a cell having human telomerase activity. Cells infected by the virus can be identified through fluorescence signals, and the higher the telomerase activity is, the stronger the fluorescence intensity is. The virus has wide application value in research of tumor action mechanisms and stem cell action mechanisms, health assessment, screening of tumor drugs, research and development of diagnostic reagents and establishment of animal models.

Disclosed herein is a chimeric nucleic acid including a human telomerase reverse transcriptase (hTERT) enhancer or a fragment thereof and an SV40 enhancer or a fragment thereof and methods of using the same.

A method of immortalizing a human keratinocyte. Also provided are immortalized human keratinocytes, for example immortalized human keratinocytes that have been immortalized using the presently disclosed method. Further provided are organotypic cultures, co-cultures, assays and kits comprising one or more immortalized human keratinocytes. In one embodiment, the immortalized human keratinocyte is produced by sequentially deleting the p16 locus, using CRISPR-Cas9 based gene editing, followed by lentiviral-based introduction of the gene encoding human telomerase reverse transcriptase (hTERT).

The invention relates to the technical field of biology, and particularly provides an immortalized cell line of a central nervous system isolated fibroid tumor (CNS SFT). The cell line is constructed through human telomerase reverse transcriptase (hTERT)-mediated lentivirus infection after primary culture of human CNS SFT tumor tissues, has stable and infinite proliferation capability, can be passaged in vitro for more than 20 generations, and keeps the characteristics of tumor cells. The cell strain expresses a feature fusion gene NAB2-STAT6 of the CNS SFT, and the feature fusion gene NAB2-STAT6 is determined to be from a CNS SFT tumor through identification. The cell strain is named as TT-SFT-6569 and is preserved in the China General Microbiological Culture Collection Center (CGMCC) on July 1, 2025, and the preservation number of the cell strain is CGMCC No.46559. The invention further discloses a preparation method of the cell strain. The cell line can be used as a CNS SFT in-vitro model, is used for screening of candidate drugs and research of a neogenesis mechanism, and provides an important tool for drug development and pathological research of CNS SFT.

The invention provides a recombinant herpes simplex virus and a preparation method thereof. The preparation method comprises the step of replacing an original ICP4 coding sequence in a herpes simplex virus genome containing an infected cell protein 4 (ICP4) gene with an hTERTp-ICP4-fluorescent protein expression cassette. The expression cassette comprises an ICP4 coding sequence and a fluorescent protein coding sequence under the control of an hTERTp promoter, and the transcription direction of the expression cassette is opposite to that of an original ICP4 promoter. The recombinant viruses are capable of selectively replicating and indicating telomerase activity in cells having human telomerase activity. Cells infected by the virus can be identified through fluorescence signals, and the higher the telomerase activity is, the stronger the fluorescence intensity is. The virus has wide application value in research of tumor action mechanisms and stem cell action mechanisms, health diagnosis, immune assessment, screening of tumor drugs, research and development of diagnostic reagents and establishment of animal models.

The invention relates to a porphyrin-G quadruplex compound and application of the porphyrin-G quadruplex compound in diagnosis and treatment of tumors. Specifically, the invention provides a nucleic acid nanocluster, which comprises a nucleic acid aptamer AS1411G-quadruplex sequence and a human telomerase-derived G-quadruplex sequence, and can be used for loading porphyrin molecules, such as a photosensitizer Ce6 and Hem with a peroxidase-like effect, so that a porphyrin-nucleic acid nanocluster compound is obtained, and the effect of diagnosing and / or treating tumors is achieved. The nucleic acid nanocluster provided by the invention has better targeting property, stability and higher drug loading capacity. The nucleic acid nanocluster loaded with Ce6 and Hem can realize a synergistic effect of multiple functions, and has an enhanced tumor inhibition function.

A consensus sequence of the antigen telomerase (ConTRt) can be generated and used in preventive and therapeutic vaccination. The consensus sequence of telomerase was generated by the fusion of two sequences, one belonging to human telomerase (hTERT) and the other to dog telomerase (dTERT), with the aim of developing an effective vaccine for the treatment of tumors expressing both human and dog telomerase, hence in both the human and veterinary sectors.

The invention belongs to the technical field of biological medicines, and provides a recombinant adeno-associated virus particle containing a targeted transcriptional melittin gene as well as a preparation method and application of the recombinant adeno-associated virus particle. Wherein the expression cassette containing the targeted transcriptional melittin gene contains a human telomerase reverse transcriptase core promoter, a tetracycline response element, an optimized melittin gene, a ribosome insertion sequence and a human enterokinase light chain-melittin fusion gene. The invention aims to solve the problem of how to realize precise targeted therapy of tumors, effectively kill tumor cells, reduce damage to normal cells to the greatest extent, overcome the limitation of a traditional treatment method and solve the problem of packaging cell death caused by advanced transcription of melittin genes in a recombinant AAV packaging process. And it is ensured that melittin expressed in tumor cells has a natural sequence and activity, and a safer and more effective treatment choice is provided for tumor patients.

The invention discloses a viral vector for accurately regulating and controlling a human telomerase gene by using a human interleukin-6 core promoter and application of the viral vector. The virus vector comprises an expression cassette with a human interleukin-6 core promoter sequence and a human telomerase gene sequence, and the human interleukin-6 core promoter sequence is activated in a natural physiological process of cell aging and inhibited in a normal cell physiological state; further accurately regulating and controlling the human telomerase gene to be expressed as telomerase protein; according to the invention, a human interleukin-6 core promoter and a human telomerase gene (hT) are respectively inserted into a virus vector to obtain the virus vector, and after the virus vector is transfected into human tissue cells, the aging of the cells can be delayed. According to the invention, the human interleukin-6 core promoter is utilized to dynamically and accurately regulate and control the expression of the human telomerase gene and construct the expression cassette and the virus vector, so that the expression cassette and the virus vector have a wide application prospect in the anti-aging and aging-related fields.

The invention relates to a recombinant lentiviral vector which comprises a gene segment composed of gene elements, and the gene elements are sequentially connected according to the following sequence: a hybrid promoter hEFH promoter, a first FRT gene, a human telomerase reverse transcriptase hTERT gene and a second FRT gene. The recombinant lentivirus can be packaged to obtain the recombinant lentivirus, and primary human urine-derived stem cells are further infected to obtain the iUSCTs. The cell strain has osteogenesis and adipogenic differentiation potentials in vitro, has the characteristics of low immunogenicity and no tumorigenicity in vivo, can induce subcutaneous ectopic osteogenesis in nude mice under the stimulation of bone morphogenetic protein 9 (BMP9), and can effectively promote skull defect repair of mice. In conclusion, the iUSCTs is a novel cell resource with great potential, and is suitable for various bone tissue regenerative medicine and cell therapy based on stem cells.

The present application discloses a mutant human telomerase RNA gene (hTERC), a nucleic acid construct and an expression vector comprising the mutant human telomerase RNA gene, and a mutant human telomerase RNA. The present application also relates to a pharmaceutical composition of the mutant human telomerase RNA gene, the nucleic acid construct, the expression vector and / or the mutant human telomerase RNA, and the use thereof in preventing or treating a tumor or delaying the progression of a tumor in a subject in need thereof.

The invention relates to a construction method of reversible immortalized human mesenchymal stem cells (ihBMSCs), which comprises the following steps: constructing a hybrid promoter hEFH formed by fusing a human elongation factor 1 alpha and an HTLV-1 promoter, human telomerase reverse transcriptase (hTERT) and a recombinant lentiviral vector containing FRT sites at two ends of the hTERT, and packaging to obtain a recombinant lentivirus; the lentivirus is used for infecting primary human bone marrow mesenchymal stem cells to obtain the ihBMSCs. Compared with primary cells, the ihBMSCs disclosed by the invention have strong in-vitro proliferation capacity and high activity, the immortalized phenotype can be recognized by an FLP-FRT system and is subjected to condition knockout so as to realize reversible deimmortalization, and the ihBMSCs have biosafety phenotypes with low immunogenicity and no tumorigenicity in vivo and can be induced to form bones in vivo and in vitro. In conclusion, the invention provides a reliable and safe seed cell for bone tissue engineering, and the seed cell has a huge application prospect in the field of stem cell treatment.

The present invention relates to cancer vaccines and methods of treatment using the same. Disclosed is a vaccine composition, the present invention relates to a composition comprising one or more nucleic acids encoding one or more amino acid sequences selected from the group consisting of a tyrosinase, a tyrosinase-associated protein 1, a tyrosinase-associated protein 2, a melanoma-associated antigen 4 protein, a growth hormone releasing hormone, a MART-1 / melan-A antigen, a cancerous testis antigen NY-ESO-1, a cancerous testis antigen NY-ESO-2, the amino acid sequences of the antigen, the Vilms tumor 1 and the human telomerase reverse transcriptase are preferentially expressed in the melanoma. The vaccine compositions may further comprise nucleic acids encoding one or more other antigens, including prostate-specific antigens. Also disclosed are methods of preventing or treating cancer in a subject in need thereof, comprising administering to the subject a vaccine composition comprising a specific amount of cancer antigens to treat or prevent a specific cancer.

Provided herein are methods of treating brain cancer in a subject, comprising evaluating one or more biological samples from a subject who has brain cancer for the presence of a miRNAs and administering interleukin-12 (IL-12); an immunogenic composition of human telomerase reverse transcriptase (hTERT), Wilms Tumor-1 (WT-1), and prostate specific membrane antigen (PSMA); and an anti-programmed cell death receptor 1 (PD-1) antibody to said subject if the subject has an increased expression level of the mIR-331-3p miRNA or isomiRs thereof and the miR-1537-3p miRNA or isomiRs thereof relative to a control population of subjects. Also provided herein are methods of treating brain cancer in a subject, comprising measuring an expression level of at least one mRNA biomarker selected from SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1, HOXD13, TGFβR3, UBA7, SFRP4, or any combination thereof, in a tumor sample from a subject and administering IL-12; an immunogenic composition hTERT, WT-1, and PSMA; and an anti-PD-1 antibody to said subject if the expression level of SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1 and HOXD13 is decreased or if the expression level of TGFβR3, UBA7, SFRP4 is increased.